
BULLETIN # 50

Manitoba Drug Benefits and Interchangeability Formulary Amendments

The following amendments will take effect on
March 13, 2006.



The amended Manitoba Specified Drug Regulation and Drug Interchangeability Formulary Regulation will be available on the Manitoba Health website

<http://www.gov.mb.ca/health/mdbif> on the effective date of **March 13, 2006**.

Bulletin 50 is currently available for download:

<http://www.gov.mb.ca/health/mdbif/bulletin50.pdf>

Inside This Issue	
Part 1 Additions	Page 1
Part 2 Deletions	Page 1
Part 3 Additions	Page 1-4
New Interchangeable Product	Page 4
Category Deletions	Page 4
Interchangeable Product Price Changes	Page 4-7

Part 1 Addition

02247056	Rhoxal-lovastatin	lovastatin	20 mg	Tablet	RXP
----------	--------------------------	------------	-------	--------	-----

Part 2 Deletions

02245058	Apo-Omeprazole <i>(Moved to Part 3)</i>	omeprazole	20 mg	Capsules	APX
02238525	HP-PAC <i>(Moved to Part 3)</i>	lansoprazole/ clarithromycin/ amoxicillin	30 mg/ 500 mg/ 500 mg	Capsule/ Tablet/ Capsule	ABB
02190915	Losec <i>(Moved to Part 3)</i>	omeprazole	20 mg	Delayed Release Tablets	AZC
00846503	Losec <i>(Moved to Part 3)</i>	omeprazole	20 mg	Capsules	AZC
--	Losec 1-2-3 A <i>(Moved to Part 3)</i>	omeprazole/ clarithromycin/ amoxicillin	20 mg/ 500 mg/ 1000 mg	Tablet/ Tablet/ Capsule	AZC
--	Losec 1-2-3 M <i>(Moved to Part 3)</i>	omeprazole/ clarithromycin/ metronidazole	20 mg/ 250 mg/ 500 mg	Tablet/ Tablet/ Tablet	AZC
02229453	Pantoloc <i>(Moved to Part 3)</i>	pantoprazole	40 mg	Enteric Coated Tablets	SOL
02243796 02243797	Pariet <i>(Moved to Part 3)</i>	rabeprazole	10 mg 20 mg	Enteric Coated Tablets	JAN
02165503 02165511	Prevacid <i>(Moved to Part 3)</i>	lansoprazole	15 mg 30 mg	Sustained Release Capsules	ABB

Part 3

The following products will be considered for Pharmacare reimbursement upon an individual prescriber/patient request basis.

02245058	Apo-Omeprazole <i>(Moved from Part 2)</i>	omeprazole	20 mg	Capsules	APX
----------	---	------------	-------	----------	-----

- (a) For the treatment of symptoms of gastroesophageal reflux disease (GERD). NOTE: Patients with non-erosive GERD could potentially be reduced to step-down therapy with an H2 antagonist depending on symptom resolution. Patients may also be trialed by dosing on alternate days or by using a lower dose PPI.
e.g. Pariet 10mg –one tablet per day instead of 2 tablets per day.
- (b) For gastro-protection for NSAID's: (The PPI may be approved for as long as the patient continues on a traditional NSAID – Coverage is renewable on a yearly basis for patients if discontinuation of offending agents or replacement with less damaging alternatives is not feasible.) For use in the prevention of NSAID induced ulcers in patients who continue on a non-selective NSAID therapy and who have any one of the following risk factors:

- History of peptic or duodenal ulcer
- Age >65 years
- Concomitant warfarin use
- Concomitant corticosteroid use

(c) For Peptic Ulcer Treatment (The PPI may be approved for 8 weeks of therapy.)

(d) For PPIs in Zollinger-Ellison Syndrome and Barrett's Esophagus
(The PPI may be approved for a 3-year treatment course.)

02238525	HP-PAC (Moved from Part 2)	lansoprazole/ clarithromycin/ amoxicillin	30 mg/ 500 mg/ 500 mg	Capsule/ Tablet/ Capsule	ABB
----------	--------------------------------------	---	-----------------------------	--------------------------------	-----

- For H. pylori eradication.

--	Losec 1-2-3 A (Moved from Part 2)	omeprazole/ clarithromycin/ amoxicillin	20 mg/ 500 mg/ 1000 mg	Tablet/ Tablet/ Capsule	AZC
----	---	---	------------------------------	-------------------------------	-----

- For H. pylori eradication.

--	Losec 1-2-3 M (Moved from Part 2)	omeprazole/ clarithromycin/ metronidazole	20 mg/ 250 mg/ 500 mg	Tablet/ Tablet/ Tablet	AZC
----	---	---	-----------------------------	------------------------------	-----

- For H. pylori eradication.

02230737 02190915 02119579 00846503	Losec (20 mg moved from Part 2)	omeprazole	10 mg 20 mg 10 mg 20 mg	Tablets/ Capsules	AZC
--	---	------------	----------------------------------	----------------------	-----

(a) For the treatment of symptoms of gastroesophageal reflux disease (GERD). NOTE: Patients with non-erosive GERD could potentially be reduced to step-down therapy with an H2 antagonist depending on symptom resolution. Patients may also be trialed by dosing on alternate days or by using a lower dose PPI.

e.g. Pariet 10mg –one tablet per day instead of 2 tablets per day.

(b) For gastro-protection for NSAID's: (The PPI may be approved for as long as the patient continues on a traditional NSAID – Coverage is renewable on a yearly basis for patients if discontinuation of offending agents or replacement with less damaging alternatives is not feasible.) For use in the prevention of NSAID induced ulcers in patients who continue on a non-selective NSAID therapy and who have any one of the following risk factors:

- History of peptic or duodenal ulcer
- Age >65 years
- Concomitant warfarin use
- Concomitant corticosteroid use

(c) For Peptic Ulcer Treatment (The PPI may be approved for 8 weeks of therapy.)

(d) For H. pylori Eradication (The PPI may be approved for a 7-14 day treatment course.)

(e) For PPIs in Zollinger-Ellison Syndrome and Barrett's Esophagus
(The PPI may be approved for a 3-year treatment course.)

2229453	Pantoloc (40 mg moved from Part 2)	pantoprazole	40 mg	Enteric Coated Tablets	SOL
---------	--	--------------	-------	---------------------------	-----

(a) For the treatment of symptoms of gastroesophageal reflux disease (GERD). NOTE: Patients with non-erosive GERD could potentially be reduced to step-down therapy with an H2 antagonist depending on symptom resolution. Patients may also be trialed by dosing on alternate days or by using a lower dose PPI.
e.g. Pariet 10mg –one tablet per day instead of 2 tablets per day.

(b) For gastro-protection for NSAID's: (The PPI may be approved for as long as the patient continues on a traditional NSAID – Coverage is renewable on a yearly basis for patients if discontinuation of offending agents or replacement with less damaging alternatives is not feasible.) For use in the prevention of NSAID induced ulcers in patients who continue on a non-selective NSAID therapy and who have any one of the following risk factors:

- History of peptic or duodenal ulcer
- Age >65 years
- Concomitant warfarin use
- Concomitant corticosteroid use

(c) For Peptic Ulcer Treatment (The PPI may be approved for 8 weeks of therapy.)

(d) For H. pylori Eradication (The PPI may be approved for a 7-14 day treatment course.)

(e) For PPIs in Zollinger-Ellison Syndrome and Barrett's Esophagus
(The PPI may be approved for a 3-year treatment course.)

Note: Omeprazole and rabeprazole must have been tried and failed or not tolerated.

02243796 02243797	Pariet (Moved from Part 2)	rabeprazole	10 mg 20 mg	Enteric Coated Tablets	JAN
----------------------	--------------------------------------	-------------	----------------	---------------------------	-----

(a) For the treatment of symptoms of gastroesophageal reflux disease (GERD). NOTE: Patients with non-erosive GERD could potentially be reduced to step-down therapy with an H2 antagonist depending on symptom resolution. Patients may also be trialed by dosing on alternate days or by use a lower dose PPI.
e.g. Pariet 10mg –one tablet per day instead of 2 tablets per day.

(b) For gastro-protection for NSAID's: (The PPI may be approved for as long as the patient continues on a traditional NSAID – Coverage is renewable on a yearly basis for patients if discontinuation of offending agents or replacement with less damaging alternatives is not feasible.) For use in the prevention of NSAID induced ulcers in patients who continue on a non-selective NSAID therapy and who have any one of the following risk factors:

- History of peptic or duodenal ulcer
- Age >65 years
- Concomitant warfarin use
- Concomitant corticosteroid use

(c) For Peptic Ulcer Treatment (The PPI may be approved for 8 weeks of therapy.)

(d) For H. pylori Eradication (The PPI may be approved for a 7-14 day treatment course.)

(e) For PPIs in Zollinger-Ellison Syndrome and Barrett's Esophagus
(The PPI may be approved for a 3-year treatment course.)

02165503 02165511	Prevacid (Moved from Part 2)	lansoprazole	15 mg 30 mg	Sustained Release Capsules	ABB
----------------------	--	--------------	----------------	----------------------------------	-----

(a) For the treatment of symptoms of gastroesophageal reflux disease (GERD). NOTE: Patients with non-erosive GERD could potentially be reduced to step-down therapy with an H2 antagonist depending on symptom resolution. Patients may also be trialed by dosing on alternate days or by using a lower dose PPI.
e.g. Pariet 10mg –one tablet per day instead of 2 tablets per day.

(b) For gastro-protection for NSAID's: (The PPI may be approved for as long as the patient continues on a traditional NSAID – Coverage is renewable on a yearly basis for patients if discontinuation of offending agents or replacement with less damaging alternatives is not feasible.) For use in the prevention of NSAID induced ulcers in patients who continue on a non-selective NSAID therapy and who have any one of the following risk factors:

- History of peptic or duodenal ulcer
- Age >65 years
- Concomitant warfarin use
- Concomitant corticosteroid use

(c) For Peptic Ulcer Treatment (The PPI may be approved for 8 weeks of therapy.)

(d) For H. pylori Eradication (The PPI may be approved for a 7-14 day treatment course.)

(e) For PPIs in Zollinger-Ellison Syndrome and Barrett's Esophagus
(The PPI may be approved for a 3-year treatment course.)

Note: Omeprazole and rabeprazole must have been tried and failed or not tolerated.

New Interchangeable Product

The following product has been added to an existing interchangeable drug category:

Lovastatin - 20 mg - Tablets					\$
	02247056	RhoXal-lovastatin	RXP		1.1998

Category Deletions

- Folic Acid - 5 mg - Tablets

Interchangeable Product Price Changes

The following changes in prices have occurred:

(\$)

00621439	Anuzinc	zinc sulfate	10 mg	Suppositories	0.3896
02241888	Arava	leflunomide	10 mg	Tablets	11.0767
02241889	Arava	leflunomide	20 mg	Tablets	11.0767
01926691	Calcimar	calcitonin	200 IU/mL	Injection	25.2670
01918311	Coumadin	warfarin	1 mg	Tablets	0.3206
01918338	Coumadin	warfarin	2 mg	Tablets	0.3391
01918346	Coumadin	warfarin	2.5 mg	Tablets	0.2714
02240205	Coumadin	warfarin	3 mg	Tablets	0.4202
02007959	Coumadin	warfarin	4 mg	Tablets	0.4202
01918354	Coumadin	warfarin	5 mg	Tablets	0.2720
01918362	Coumadin	warfarin	10 mg	Tablets	0.4879
00344877	Cytosan	cyclophosphamide	25 mg	Tablets	0.4096
00344885	Cytosan	cyclophosphamide	50 mg	Tablets	0.5516
02224550	Diabeta	glyburide	2.5 mg	Tablets	0.1218
02224569	Diabeta	glyburide	5 mg	Tablets	0.2182
01997629	Didronel	etidronate disodium	200 mg	Tablets	1.5246

Bulletin #50
Effective: March 13, 2006

01916548	Endocet	oxycodone HCl/ acetaminophen	5 mg/325 mg	Tablets	0.1414
02244000	Estradot	estradiol 17B/estrogen	50 mcg	Transdermal Patch	2.8174
02244001	Estradot	estradiol 17B/estrogen	75 mcg	Transdermal Patch	3.0250
02244002	Estradot	estradiol 17B/estrogen	100 mcg	Transdermal Patch	3.1790
02099233	Glucophage	metformin	500 mg	Tablets	0.2541
02162849	Glucophage	metformin	850 mg	Tablets	0.3220
00230316	Hycort	hydrocortisone	100 mg/60 mL	Enema	5.6572
01926799	Imovane	zopiclone	7.5 mg	Tablets	0.9138
02026961	Kayexalate	sodium polystyrene sulfonate	454 g	Oral Powder	0.1670
02031116	Lamisil	terbinafine	250 mg	Tablets	4.4566
02224690	Lasix	furosemide	20 mg	Tablets	0.0796
02224704	Lasix	furosemide	40 mg	Tablets	0.1221
00115630	Librax	chlordiazepoxide HCl/clindium bromide	5 mg/2.5 mg	Capsules	0.3240
00455881	Lioresal	baclofen	10 mg	Tablets	0.6061
00636576	Lioresal D.S.	baclofen	20 mg	Tablets	1.1798
02146959	Lipidil Micro	fenofibrate	200 mg	Capsules	1.1979
00397423	Lopressor	metoprolol	50 mg	Tablets	0.2522
00397431	Lopressor	metoprolol	100 mg	Tablets	0.5172
00731323	Megace	megestrol acetate	160 mg	Tablets	6.2524
02240775	Miacalcin NS	calcitonin (salmon synthetic)	200 IU	Nasal Spray	2.0225
00511528	Mogadon	nitrazepam	5 mg	Tablets	0.1571
00511536	Mogadon	nitrazepam	10 mg	Tablets	0.2351
01907107	Monopril	fosinopril	10 mg	Tablets	0.8951
01907115	Monopril	fosinopril	20 mg	Tablets	1.0766
00514217	M.O.S	morphine hydrochloride	5 mg/mL	Syrup	0.0926
00632481	M.O.S	morphine hydrochloride	20 mg/mL	Syrup	0.5764
01927620	Myochrysin	sodium aurothiomalate	10 mg/mL	Injection	10.934
01927604	Myochrysin	sodium aurothiomalate	50 mg/mL	Injection	20.6030
02229655	Nitrazadon	nitrazepam	10 mg	Tablets	0.1411
00020877	Novo-Ampicillin	ampicillin	250 mg	Capsules	0.3071
00020885	Novo-Ampicillin	ampicillin	500 mg	Capsules	0.5955
00628190	Novo-Clopat	clorazepate	3.75 mg	Capsules	0.1067
00628204	Novo-Clopat	clorazepate	7.5 mg	Capsules	0.1926
00628212	Novo-Clopat	clorazepate	15 mg	Capsules	0.3856
02048493	Novo-Diflunasal	diflunisal	250 mg	Tablets	0.5647
02048507	Novo-Diflunasal	diflunisal	500 mg	Tablets	0.6907
01913425	Novo-Doxepin	doxepin	25 mg	Capsules	0.2140
01913433	Novo-Doxepin	doxepin	50 mg	Capsules	0.3971
01913441	Novo-Doxepin	doxepin	75 mg	Capsules	0.5702
01913468	Novo-Doxepin	doxepin	100 mg	Capsules	0.7513
01913476	Novo-Doxepin	doxepin	150 mg	Capsules	1.1270
00759465	Novo-Hylazin	hydralazine	10 mg	Tablets	0.1026
00759473	Novo-Hylazin	hydralazine	25 mg	Tablets	0.1764
00759481	Novo-Hylazin	hydralazine	50 mg	Tablets	0.2770
00738824	Novo-Hydroxyzin	hydroxyzine	10 mg	Capsules	0.1116
00738832	Novo-Hydroxyzin	hydroxyzine	25 mg	Capsules	0.1425
00738840	Novo-Hydroxyzin	hydroxyzine	50 mg	Capsules	0.2068
01934198	Novo-Prazin	prazosin	1 mg	Tablets	0.2055

Bulletin #50
Effective: March 13, 2006

01934201	Novo-Prazin	prazosin	2 mg	Tablets	0.2791
01934228	Novo-Prazin	prazosin	5 mg	Tablets	0.3806
00364282	Novo-Purol	allopurinol	100 mg	Tablets	0.0780
00565342	Novo-Purol	allopurinol	200 mg	Tablets	0.1300
00363693	Novo-Purol	allopurinol	300 mg	Tablets	0.2125
01947796	Novo-Timol	timolol maleate	5 mg	Tablets	0.1817
01947818	Novo-Timol	timolol maleate	10 mg	Tablets	0.2835
00532657	Novo-Triamzide	triamterene/ hydrochlorothiazide	50 mg/25 mg	Tablets	0.0608
02042991	Os-Cal	calcium carbonate	500 mg	Tablets	0.1381
02017709	Planquenil	hydroxychloroquine sulfate	200 mg	Tablets	0.6053
01916386	pms-Hydromorphone	hydromorphone	1 mg/mL	Oral Liquid	0.0718
02230433	pms-Metoclopramide	metoclopramide	5 mg/5 mL	Oral Solution	0.0402
00893749	Pravachol	pravastatin sodium	10 mg	Tablets	1.7146
00893757	Pravachol	pravastatin sodium	20 mg	Tablets	2.0226
02222051	Pravachol	pravastatin sodium	40 mg	Tablets	2.4362
02171791	ratio-Atenolol	atenolol	50 mg	Tablets	0.3867
02246825	ratio-Ciprofloxacin	ciprofloxacin	250 mg	Tablets	**1.5391
02246826	ratio-Ciprofloxacin	ciprofloxacin	500 mg	Tablets	**1.7365
02246827	ratio-Ciprofloxacin	ciprofloxacin	750 mg	Tablets	**3.2751
02243789	ratio-Ipra Sal UVD	ipratropium bromide/salbutamol	0.2 mg/ 1 mg/mL	Unit Dose Vial	0.4069
02091887	Rifadin	rifampin	150 mg	Capsules	0.7323
02092808	Rifadin	rifampin	300 mg	Capsules	1.1525
00005606	Ritalin	methylphenidate	10 mg	Tablets	0.3207
00005614	Ritalin	methylphenidate	20 mg	Tablets	0.5604
00739839	Sandoz Dexamethasone	dexamethasone	0.1%	Ophthalmic/ Otic Solution	1.1000
01926543	Sectral	acebutalol	100 mg	Tablets	0.3140
01926551	Sectral	acebutalol	200 mg	Tablets	0.4710
01926578	Sectral	acebutalol	400 mg	Tablets	0.9371
00870935	Sinemet CR	levodopa/carbidopa	200 mg/50 mg	Tablets	1.3345
02224623	Sofracort	framycetin sulfate/ gramicidin/ dexamethasone	5 mg/ 0.05 mg/ 0.5 mg/mL	Otic/ Ophthalmic Solution	1.6982
02221950	Surgam	tiaprofenic acid	300 mg	Tablets	0.7902
00010405	Tegretol	carbamazepine	200 mg	Tablets	0.3505
00369810	Tegretol	carbamazepine	100 mg	Chewable Tablets	0.1471
00665088	Tegretol	carbamazepine	200 mg	Chewable Tablets	0.2901
00773611	Tegretol CR	carbamazepine	200 mg	Sustained Release Tablets	0.3602
00755583	Tegretol CR	carbamazepine	400 mg	Sustained Release Tablets	0.7203
02221977	Trental	pentoxifylline	400 mg	Tablets	0.7407
00417270	Visken	pindolol	5 mg	Tablets	0.5172
00443174	Visken	pindolol	10 mg	Tablets	0.8831
00417289	Visken	pindolol	15 mg	Tablets	1.2811
00521515	Vitamin B12	cyanocobalamin	1 mg/mL	Injection	0.4950
00632724	Voltaren	diclofenac sodium	50 mg	Suppositories	1.1778
00632732	Voltaren	diclofenac sodium	100 mg	Suppositories	1.5859

Bulletin #50
Effective: March 13, 2006

00514012	Voltaren	diclofenac sodium	50 mg	Tablets	0.7846
00881635	Voltaren Rapide	diclofenac potassium	50 mg	Tablets	0.7520
00782459	Voltaren SR	diclofenac sodium	75 mg	Slow Release Tablets	1.1025
00590827	Voltaren SR	diclofenac sodium	100 mg	Slow Release Tablets	1.5714
01926551	Sectral	acebutalol	200 mg	Tablets	0.4710
01926578	Sectral	acebutalol	400 mg	Tablets	0.9371
00870935	Sinemet CR	levodopa/carbidopa	200 mg/50 mg	Tablets	1.3345
02224623	Sofracort	framycetin sulfate/ gramicidin/ dexamethasone	5 mg/ 0.05 mg/ 0.5 mg/mL	Otic/ Ophthalmic Solution	1.6982
02221950	Surgam	tiaprofenic acid	300 mg	Tablets	0.7902
00010405	Tegretol	carbamazepine	200 mg	Tablets	0.3505
00369810	Tegretol	carbamazepine	100 mg	Chewable Tablets	0.1471
00665088	Tegretol	carbamazepine	200 mg	Chewable Tablets	0.2901
00773611	Tegretol CR	carbamazepine	200 mg	Sustained Release Tablets	0.3602
00755583	Tegretol CR	carbamazepine	400 mg	Sustained Release Tablets	0.7203
02221977	Trental	pentoxifylline	400 mg	Tablets	0.7407
00718149	Tryptan	L-tryptophan	500 mg	Capsules	0.7838
02029456	Tryptan	L-tryptophan	500 mg	Tablets	0.7838
00654531	Tryptan	L-tryptophan	1 g	Tablets	1.5677
00417270	Visken	pindolol	5 mg	Tablets	0.5172
00443174	Visken	pindolol	10 mg	Tablets	0.8831
00417289	Visken	pindolol	15 mg	Tablets	1.2811
00521515	Vitamin B12	cyanocobalamin	1 mg/mL	Injection	**0.4950 (0.3410)
00632724	Voltaren	diclofenac sodium	50 mg	Suppositories	1.1778
00632732	Voltaren	diclofenac sodium	100 mg	Suppositories	1.5859
00514012	Voltaren	diclofenac sodium	50 mg	Tablets	0.7846
00881635	Voltaren Rapide	diclofenac potassium	50 mg	Tablets	0.7520
00782459	Voltaren SR	diclofenac sodium	75 mg	Slow Release Tablets	1.1025
00590827	Voltaren SR	diclofenac sodium	100 mg	Slow Release Tablets	1.5714
00271373	Winpred	prednisone	1 mg	Tablets	0.1139

** The price change has resulted in a change to the lowest price in the category.

() Denotes the price of the lowest generic product in the product category.